Top alert for 2014: MYGN (50%), LIVE (45%), CTIC (115%), KOOL (88%), PZG (32%), GOLD (6%), IOC (6%), RSOL(18%), PLUG (70%), IMMU (26%)

Tuesday, January 21, 2014

Premarket Summary for January 21st: CTIC, AMRN, PSTI, GPS, NQ, PATH, BCRX, VVUS, AUXL, ADXS, SRPT, BLRX, GALT, ICPT

Premarket Summary:

CTIC:  Our best pick of 2014 
http://stocktwits.com/message/19163866

AMRN Amarin announces FDA DMEP 'does not plan to reinstate ANCHOR SPA agreement'.

PSTI   Pluristem muscle injury trial meets primary safety, efficacy endpoints.

GPS   Gap upgraded to Buy from Underperform at Sterne Agee YGE Yingli Green obtains certificate for contracting foreign projects from PRC.

NQ  Altimeter reports NQ Mobile stake of 9.9% with rights to acquire 7.4% more.

ENDP, PATH Endo Health announces NuPathe terminated merger agreement.

BCRX   BioCryst initiated with a Buy at Roth Capital Target $18.

 VVUS, AUXL   VIVUS and Auxilium announces FDA accepted STENDRA's supplemental application PDUFA date is September 20, 2014.

SRPT Needham upgraded Sarepta due to valuation and continued positive data from the eteplirsen Phase IIb trial. Price target is $36.

ADXS Advaxis announces first patient dosed in Phase 1/2 ADXS-HPV GALT Preclinical study shows effect of Galectin GR-MD-02 on serum biomarker on NASH.

BLRX  BioLineRx receives approval to commence pivotal trial for novel skin lesion treatment

GALT Preclinical study shows effect of Galectin GR-MD-02 on serum biomarker on NASH

Other Active Stock to watch:
ICPT, NLST, CHTP, JRCC, RTRX

For Further reading join our Premium services http://www.freefdawatchlist.com/p/our-services.html


No comments:

Post a Comment